Preliminary results for the year ended 30 June 2009

Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, announces its preliminary results for the year ended 30 June 2009.

Key points

• Discussions ongoing regarding potential collaboration on further development and commercialisation of NPL-2008 in Autistic Disorder
• Pipeline expanded with two new near-term revenue-generating opportunities
  - NPL-2505, a branded pharmaceutical targeting a substantial patient population
  - NPL-2510, a novel biological screen for autism
• Positive Phase IIa results from NPL-2009 and NPL-2005 have placed Neuropharm at the forefront of Fragile X Syndrome research
• Patent filing in connection with NPL-2003 in Obsessive Compulsive Disorder, focused on the treatment of child-onset OCD
• Cash cash equivalents and money market investments at 30 June 2009 of £7.0 million (2008: £12.7 million)

For further information please contact:

Neuropharm + 44 (0) 1372 371 171

Robert Mansfield, Chief Executive Officer

Graham Yeatman, Chief Financial Officer

Piper Jaffray Limited + 44 (0) 203 142 8700

Neil Mackison, Rupert Winckler

Buchanan Communications + 44 (0) 207 466 5000

Mark Court, Catherine Breen

Notes to Editors:

About Neuropharm

Neuropharm is a speciality pharmaceutical company focused on the development of products for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.uk for further information.

Neuropharm plc preliminary results for year ended 30th June 2009

(PDF 50KB)